Reni Benjamin analyst

Currently out of the existing stock ratings of Reni Benjamin, 287 are a BUY (88.58%), 37 are a HOLD (11.42%).

Reni Benjamin

Work Performance Price Targets & Ratings Chart

Analyst Reni Benjamin, has had 47.22% of price targets met with an average potential upside of 47.18%, reached in 267 days on average. Previously, Reni Benjamin worked at RAYMOND JAMES, HC WAINWRIGHT.

Reni Benjamin has documented 593 price targets and ratings displayed on 45 stocks. The coverage was on the Healthcare sector.

Most recent stock forecast was given on ZYME, Zymeworks.

Wall Street Analyst Reni Benjamin

Analyst best performing recommendations are on IOVA (IOVANCE BIOTHERAPEUTICS).
The best stock recommendation documented was for IOVA (IOVANCE BIOTHERAPEUTICS) on 3/3/2026. The price target of $5 was fulfilled within 3 days with a profit of $1.25 (33.33%), with a performance score of 111.11.

Average potential price target upside

BCYC Bicycle Therapeutics Ltd BPMC Blueprint Medicines Corp DCPH Deciphera Pharmaceuticals LLC EFTR Effector Therapeutics INBX Inhibrx INCY yte IOVA Iovance Biotherapeutics SGEN Seagen STRO Sutro Biopharma VYGR Voyager Therapeutics ALLO Allogene Therapeutics CGEN Compugen KURA Kura Oncology ACET Adicet Bio CTIC CTi Biopharma Corp RGNX Regenxbio ADAP Adaptimmune Therapeutics Plc ADVM Adverum Biotechnologies BCAB Bioatla CUE Cue Biopharma SPPI Spectrum Pharmaceuticals URGN UroGen Pharma Ltd AMAM Ambrx Biopharma LVTX LAVA Therapeutics NV SANA Sana Biotechnology VSTM Verastem HOWL Werewolf Therapeutics PRLD Prelude Therapeutics AKBA Akebia Ther IDRA Idera Pharmaceuticals SMMT Summit Therapeutics PLC TIL Instil Bio ADMA ADMA Biologics BMRN Biomarin Pharmaceutical BTX Brooklyn Immunotherapeutics NXTC NextCure SG Sweetgreen TRIL Trillium Therapeutics BCAX Bicara Therapeutics CMPX Compass Therapeutics LYEL Lyell Immunopharma ZYME Zymeworks CNST Constellation Pharmaceuticals IMMP Immutep Ltd ADR ONCE Spark Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy Since 02-Mar-2022

$14

$10.63 (315.43%)

$15

3 months 18 days ago
(30-Jul-2026)

0/25 (0%)

$9.99 (249.13%)

Buy Since 20-Apr-2021

$8

$4.63 (137.39%)

$8

5 months 14 days ago
(03-Jun-2026)

1/17 (5.88%)

$3.8 (90.48%)

174

Hold Since 14-Feb-2022

$12

$8.63 (256.08%)

$13

7 months 9 days ago
(08-Apr-2026)

0/10 (0%)

$7.02 (140.96%)

Hold Since 18-Mar-2026

$7

$3.63 (107.72%)

$11

7 months 30 days ago
(18-Mar-2026)

0/4 (0%)

$2.3 (48.94%)

Buy Since 11-Jun-2020

$36

$32.63 (968.25%)

7 months 30 days ago
(18-Mar-2026)

3/10 (30%)

$31.3 (665.96%)

192

Show more analysts

Please expand the browser size to see the chart

Which stock is Reni Benjamin most bullish on?

Potential upside of $24.41 has been obtained for STRO (SUTRO BIOPHARMA)

Which stock is Reni Benjamin most reserved on?

Potential downside of $2.55 has been obtained for PRLD (PRELUDE THERAPEUTICS)
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?